An FDA advisory panel has narrowly recommended allowing compounding pharmacies to produce two unapproved peptides, BPC 157 and KPV, despite concerns about their safety and efficacy. The decision, influenced by advocacy from Robert F. Kennedy Jr. and others, marks a significant shift in regulatory policy. While proponents argue the peptides offer therapeutic potential for conditions like inflammatory bowel disease, critics warn of risks due to insufficient clinical evidence and lack of FDA approval.
An FDA advisory panel voted by a narrow margin to permit compounding pharmacies to produce two unapproved peptides, BPC 157 and KPV, which have gained popularity despite lacking regulatory approval. The decision follows intense lobbying efforts, including advocacy from independent presidential candidate Robert F. Kennedy Jr., who has publicly supported the use of these peptides for their purported healing properties.
The panel's recommendation does not grant immediate approval but signals a potential shift in the FDA's stance on compounded peptides. The agency has historically restricted compounding of unapproved drugs due to safety concerns, but this vote suggests a willingness to reconsider under specific conditions.
DISCUSSION (0)